ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable residual disease (MRD)-negative responses in the first four patients with relapsed ...
At the ASCGT meeting, scientists reported that Carvykti-treated cells overexpressed the enzyme Granzyme K, which may be ...
London, UK-based Cytospire said this morning that it has raked in £61 million ($83 million) in the round, which will fund its ...
A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...
The Brighterside of News on MSN
Study finds low-dose CAR T therapy can drive complete cancer remission
A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For ...
The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.
Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results